簡(jiǎn)要描述:急性淋巴細(xì)胞性白血病1抗體注意事項(xiàng);This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
商品屬性:
貨號(hào) | 產(chǎn)品名稱 | 規(guī)格 |
GOY-01K5130 | 急性淋巴細(xì)胞性白血病1抗體 | 50ul |
GOY-01K5130 | 急性淋巴細(xì)胞性白血病1抗體 | 100ul |
GOY-01K5130 | 急性淋巴細(xì)胞性白血病1抗體 | 200ul |
英文名稱: KMT2A
中文名稱: 急性淋巴細(xì)胞性白血病1抗體
別 名;Acute lymphocytic leukemia 1; ALL 1; ALL-1;
ALL1; C-terminal cleavage product of 180 kDa; CXXC 7; CXXC-type zinc finger
protein 7; CXXC7; HRX; HTRX 1; HTRX1; KMT2A; Lysine N-methyltransferase 2A; MLL
1A; Mll; MLL cleavage product C180; MLL1; MLL1_HUMAN; MLL1A; Myeloid/lymphoid
or mixed lineage leukemia; N-terminal cleavage product of 320 kDa; p180; p320;
Trithorax homolog; Trithorax homolog Drosophila; Trithorax like protein;
Trithorax-like protein; TRX 1; TRX1; Zinc finger protein HRX.
研究領(lǐng)域;腫瘤 細(xì)胞生物 免疫學(xué) 淋巴細(xì)胞 t-淋巴細(xì)胞 b-淋巴細(xì)胞 表觀遺傳學(xué)
抗體來(lái)源;Rabbit
克隆類型;Polyclonal
交叉反應(yīng);(predicted: Human, Mouse, Rat,
Dog, Pig, Cow, Horse, Rabbit, )
產(chǎn)品應(yīng)用;ELISA=1:5000-10000
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;432kDa
細(xì)胞定位;細(xì)胞核
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH conjugated synthetic
peptide derived from human KMT2A: 3801-3969/3969
亞 型;IgG
純化方法;affinity purified by Protein A
緩 沖 液;0.01M TBS(pH7.4) with 1% BSA,
0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng);This product as supplied is
intended for research use only, not for use in human, therapeutic or diagnostic
applications.
產(chǎn)品介紹 This gene encodes a
transcriptional coactivator that plays an essential role in regulating gene
expression during early development and hematopoiesis. The encoded protein
contains multiple conserved functional domains. One of these domains, the SET
domain, is responsible for its histone H3 lysine 4 (H3K4) methyltransferase
activity which mediates chromatin modifications associated with epigenetic
transcriptional activation. This protein is processed by the enzyme Taspase 1
into two fragments, MLL-C and MLL-N. These fragments reassociate and further
assemble into different multiprotein complexes that regulate the transcription
of specific target genes, including many of the HOX genes. Multiple chromosomal
translocations involving this gene are the cause of certain acute lymphoid
leukemias and acute myeloid leukemias. Alternate splicing results in multiple
transcript variants.[provided by RefSeq, Oct 2010]
Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'. Required for transcriptional activation of HOXA9. Promotes PPP1R15A-induced apoptosis.
實(shí)驗(yàn)流程:
(1)特異性結(jié)合抗原:抗體本身不能直接溶解或殺傷帶有特異抗原的靶細(xì)胞,通常需要補(bǔ)體或吞噬細(xì)胞等共同發(fā)揮效應(yīng)以清除病原微生物或?qū)е虏±頁(yè)p傷。然而,抗體可通過(guò)與病毒或毒素的特異性結(jié)合,直接發(fā)揮中和病毒的作用。
(2)活補(bǔ)體:IgM、IgG1、IgG2和IgG3可通過(guò)經(jīng)典途徑激活補(bǔ)體,凝聚的IgA、IgG4和IgE可通過(guò)替代途徑激活補(bǔ)體。
(3)結(jié)合細(xì)胞:不同類別的免疫球蛋白,可結(jié)合不同種的細(xì)胞,參與免疫應(yīng)答。
(4)可通過(guò)胎盤及粘膜:免疫球蛋白G(IgG)能通過(guò)胎盤進(jìn)入胎兒血流中,使胎兒形成自然被動(dòng)
免疫。免疫球蛋白A(IgA)可通過(guò)消化道及呼吸道粘膜,是粘膜局部抗感染免疫的主要因素。
(5)具有抗原性:抗體分子是一種蛋白質(zhì),也具有刺機(jī)體產(chǎn)生免疫應(yīng)答的性能。不同的免疫球蛋白分子,各具有不同的抗原性。
(6)抗體對(duì)理化因子的抵抗力與一般球蛋白相同:不耐熱,60~70℃即被破壞。各種酶及能使蛋白質(zhì)凝固變性的物質(zhì),均能破壞抗體的作用。抗體可被中性鹽類沉淀。在生產(chǎn)上常可用硫酸銨或硫酸鈉從免疫血清中沉淀出含有抗體的球蛋白,再經(jīng)透析法將其純化。
抗體的制備過(guò)程:
1.免疫原:普通的大分子蛋白,通過(guò)分子克隆構(gòu)建載體并在大腸桿菌中進(jìn)行誘導(dǎo)表達(dá)獲得重組蛋白,純化鑒定后可直接作為免疫原;小分子蛋白或化合物等分子量小,需要偶聯(lián)載體對(duì)該分子進(jìn)行改造才能使其成為具有免疫原性的抗原,常見偶聯(lián)載體如BSA、OVA、HAS等。
2. 免疫動(dòng)物:常用于制備抗血清的動(dòng)物有豚鼠、家兔、雞、大小鼠等,大量生產(chǎn)時(shí)需要用到狗、綿羊、山羊等。
3.免疫血清的收集:一般家兔、綿羊、山羊可采用靜動(dòng)脈采血,家兔、豚鼠、大鼠、雞可采用心臟采血,家兔、山羊、綿羊可采用靜脈采血。
4. 急性淋巴細(xì)胞性白血病1抗體免疫血清的純化與鑒定:得到的抗血清需要進(jìn)一步的純化,利用偶聯(lián)了抗原的親和柱進(jìn)行層析,具有高效,特異性強(qiáng),純度高的特定。接著要鑒定純化蛋白的含量、相對(duì)分子的質(zhì)量、純度以及特異性。
5.免疫血清的保存:抗體一般比較穩(wěn)定,在-80℃ ~-20 ℃可以保存約5年而不會(huì)影響效價(jià),而真空干燥保存時(shí)間可以更久。保存前需經(jīng)除菌并添加防腐劑。
產(chǎn)品咨詢
歡迎您關(guān)注我們的微信了解更多信息
電話
微信掃一掃